| Quantity | 1 mg, 5 mg | 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | 5 mg, 10 mg | 500 µ, g, 1 mg, 5 mg |
| Description | GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on GLP-2 receptor (EC50=5.8 nM)[1][2] | Glucagon (1-29), bovine, human, porcine is a peptide hormone, produced by pancreatic α-cells. Glucagon stimulates gluconeogenesis[1]. Glucagon (1-29), bovine, human, porcine activates HNF4α and increases HNF4α phosphorylation[2][3] | Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis[1][2][3][4][5][6]... Read More | MOG (35-55) (MOG (35-55)) TFA is a minor component of CNS myelin. MOG (35-55) (TFA) has encephalitogenic activity and induces T cell proliferative. MOG (35-55) (TFA) induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) (TFA) produces a relapsing-MOG (35-55) (MOG (35-55)) TFA is a minor component of CNS myelin. MOG (35-55) (TFA) has encephalitogenic activity and induces T cell proliferative. MOG (35-55) (TFA) induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) (TFA) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) (MOG (35-55)) TFA can be used for experimental autoimmune encephalomyelitis (EAE) modeling[1][2][3]... Read More | PACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor agonist with IC50s of 3 nM, 2 nM and 5 nM for rat PAC1, rat VPAC1 and human VPAC2, respectively[1] |